Atlas Trials

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Clinical trial NCT03088176 · UNKNOWN

Trial details

NCT number
NCT03088176
Sponsor
West Cancer Center
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
MelanomaBRAF Gene Mutation
Start date
2017-06-25
Primary completion
2020-11-30
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.